Large-scale testing (Phase 3)Study completedNCT01038661What this trial is testingTax First-line Chemotherapy With Different Doses and Then Maintenance TherapyWho this might be right forLung Neoplasms Sanofi 375
Not applicableEnded earlyNCT00087191What this trial is testingEF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerWho this might be right forAdvanced Adult Primary Liver CancerCarcinoma of the AppendixFallopian Tube Cancer+68 more National Cancer Institute (NCI) 30
Early research (Phase 1)Study completedNCT00020579What this trial is testingMS-275 in Treating Patients With Advanced Solid Tumors or LymphomaWho this might be right forCancer National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Study completedNCT01155258What this trial is testingTemsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsWho this might be right forExtensive Stage Small Cell Lung CancerHereditary ParagangliomaMale Breast Cancer+45 more University of Southern California 19
Testing effectiveness (Phase 2)UnknownNCT05745740What this trial is testingRC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationWho this might be right forNon-small Cell Lung Cancer RemeGen Co., Ltd. 26
Testing effectiveness (Phase 2)Active Not RecruitingNCT06391944What this trial is testingJMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common MutationsWho this might be right forLocal Advanced or Metastatic NSCLCHarboring EGFR Common Mutation Shanghai JMT-Bio Inc. 161
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348What this trial is testingJMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsWho this might be right forLocal Advanced or Metastatic NSCLC Shanghai JMT-Bio Inc. 398
Testing effectiveness (Phase 2)Active Not RecruitingNCT05941897What this trial is testingInvestigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyWho this might be right forAdvanced or Metastatic NSCLC AstraZeneca 39
Large-scale testing (Phase 3)Active Not RecruitingNCT05668988What this trial is testingDZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Who this might be right forNon-small Cell Lung Cancer Dizal Pharmaceuticals 324
Large-scale testing (Phase 3)Study completedNCT00478049What this trial is testingIressa as Second Line Therapy in Advanced NSCLC-AsiaWho this might be right forNSCLC AstraZeneca 163
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06182761What this trial is testingSunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung CancerWho this might be right forNSCLC Shanghai Zhongshan Hospital 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07294261What this trial is testingGarsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCWho this might be right forLocal Advanced or Metastatic NSCLC Sun Yat-sen University 69
Early research (Phase 1)Looking for participantsNCT06427941What this trial is testingBGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsWho this might be right forMetastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more BeOne Medicines 392
Testing effectiveness (Phase 2)UnknownNCT04872634What this trial is testingEvaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor TreatmentWho this might be right forNon-small Cell Lung Cancer NKMAX Co., Ltd. 24
Large-scale testing (Phase 3)UnknownNCT05111197What this trial is testingLocal Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to ImmunotherapyWho this might be right forLocally Advanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer Institut Cancerologie de l'Ouest 112
Early research (Phase 1)UnknownNCT04059874What this trial is testingTreatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene SulfonateWho this might be right forNon-small Cell Lung Cancer First Affiliated Hospital of Zhejiang University 20
Early research (Phase 1)Ended earlyNCT01282333What this trial is testingVeliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerWho this might be right forAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and Ureter+11 more National Cancer Institute (NCI) 44
Large-scale testing (Phase 3)Ended earlyNCT02766140What this trial is testingSHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerWho this might be right forNon Squamous Non Small Cell Lung Jiangsu HengRui Medicine Co., Ltd. 12
Testing effectiveness (Phase 2)UnknownNCT04974879What this trial is testingOsimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Qingdao Central Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00016367What this trial is testingCisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerWho this might be right forLung Cancer M.D. Anderson Cancer Center 22